Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges
Matthew R. Gardner, Christoph H. Fellinger, Lisa Kattenhorn, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 502
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China
Robert L. Kruse
F1000Research (2020) Vol. 9, pp. 72-72
Open Access | Times Cited: 277
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
Steven G. Deeks, Nancie M. Archin, Paula M. Cannon, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2085-2098
Open Access | Times Cited: 251
The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement
Brian D. Quinlan, Huihui Mou, Lizhou Zhang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 137
Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China
Robert L. Kruse
F1000Research (2020) Vol. 9, pp. 72-72
Open Access | Times Cited: 99
In vivo affinity maturation of the CD4 domains of an HIV-1-entry inhibitor
Andi Pan, Charles C. Bailey, Tianling Ou, et al.
Nature Biomedical Engineering (2024)
Closed Access | Times Cited: 5
Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV
José M. Martinez-Navío, Sebastian Fuchs, Desiree E. Mendes, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 37
Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?
Wei Zhan, Manish Muhuri, Phillip W.L. Tai, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 28
High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes
Matthew R. Gardner, Desiree E. Mendes, Cláudia P. Muniz, et al.
Molecular Therapy — Methods & Clinical Development (2022) Vol. 24, pp. 199-206
Open Access | Times Cited: 19
SHIV fights back to evade destruction by eCD4-Ig but not without suffering debilitating wounds
Eric J. Arts
Molecular Therapy (2025)
Closed Access
Adeno-associated viral delivery of Env-specific antibodies prevents SIV rebound after discontinuing antiretroviral therapy
Vadim A. Klenchin, Natasha M. Clark, Nida K. Keles, et al.
Science Immunology (2025) Vol. 10, Iss. 104
Open Access
Engineering hematopoietic stem and progenitor cells to generate red blood cells as viral traps against HIV-1
Sofia E. Luna, William N. Feist, Kaya Ben-Efraim, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Promise and Progress of an HIV-1 Cure by Adeno-Associated Virus Vector Delivery of Anti-HIV-1 Biologics
Matthew R. Gardner
Frontiers in Cellular and Infection Microbiology (2020) Vol. 10
Open Access | Times Cited: 28
Small Molecule HIV-1 Attachment Inhibitors: Discovery, Mode of Action and Structural Basis of Inhibition
Yen‐Ting Lai
Viruses (2021) Vol. 13, Iss. 5, pp. 843-843
Open Access | Times Cited: 27
New era of optogenetics: from the central to peripheral nervous system
Xiang Xu, Thomas Mee, Xiaofeng Jia
Critical Reviews in Biochemistry and Molecular Biology (2020) Vol. 55, Iss. 1, pp. 1-16
Open Access | Times Cited: 26
Sulfotyrosine residues: Interaction specificity determinants for extracellular protein–protein interactions
Valley Stewart, Pamela C. Ronald
Journal of Biological Chemistry (2022) Vol. 298, Iss. 8, pp. 102232-102232
Open Access | Times Cited: 16
A lentiviral vector B cell gene therapy platform for the delivery of the anti-HIV-1 eCD4-Ig-knob-in-hole-reversed immunoadhesin
Eirini Vamva, Stosh Ozog, Daniel P. Leaman, et al.
Molecular Therapy — Methods & Clinical Development (2023) Vol. 28, pp. 366-384
Open Access | Times Cited: 8
Adeno-associated virus-vectored delivery of HIV biologics: the promise of a “single-shot” functional cure for HIV infection
P. Hahn, Maurício A. Martins
Journal of Virus Eradication (2023) Vol. 9, Iss. 1, pp. 100316-100316
Open Access | Times Cited: 8
eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody
Christoph H. Fellinger, Matthew R. Gardner, Jesse A. Weber, et al.
Journal of Virology (2019) Vol. 93, Iss. 14
Open Access | Times Cited: 25
Liver-Directed but Not Muscle-Directed AAV-Antibody Gene Transfer Limits Humoral Immune Responses in Rhesus Monkeys
Sebastian Fuchs, José M. Martinez-Navío, Eva G. Rakasz, et al.
Molecular Therapy — Methods & Clinical Development (2019) Vol. 16, pp. 94-102
Open Access | Times Cited: 25
Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure
Jeffrey C. Umotoy, Steven W. de Taeye
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 18
Opening the HIV envelope: potential of CD4 mimics as multifunctional HIV entry inhibitors
Annemarie Laumaea, Amos B. Smith, Joseph Sodroski, et al.
Current Opinion in HIV and AIDS (2020) Vol. 15, Iss. 5, pp. 300-308
Open Access | Times Cited: 18
Delivery platforms for broadly neutralizing antibodies
Lok R. Joshi, Nicolás M. S. Gálvez, Sukanya Ghosh, et al.
Current Opinion in HIV and AIDS (2023)
Open Access | Times Cited: 6
Optogenetics for Understanding and Treating Brain Injury: Advances in the Field and Future Prospects
Yuwen Sun, Manrui Li, Shuqiang Cao, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1800-1800
Open Access | Times Cited: 9
A strategy for high antibody expression with low anti-drug antibodies using AAV9 vectors
Meredith E. Davis-Gardner, Jesse A. Weber, Jun Xie, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Recent Advancements in AAV-Vectored Immunoprophylaxis in the Nonhuman Primate Model
Elena S. B. Campbell, Melanie M. Goens, Wenguang Cao, et al.
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2223-2223
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top